

November 29, 2013



Cardax Pharma, Inc. Enters Into a Definitive Merger Agreement With Koffee Korner, Inc.

Honolulu, Hawaii—November 29, 2013—Cardax Pharmaceuticals, Inc. (“Cardax Pharmaceuticals”) and its wholly owned subsidiary Cardax Pharma, Inc. (“Cardax Pharma”), a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, including products based on its proprietary astaxanthin technologies, are pleased to announce that they have entered into a definitive merger agreement with Koffee Korner, Inc. (“Koffee Korner”) (OTCBB: KOFF), and its wholly owned subsidiary. Under the terms of the definitive merger agreement, Koffee Korner will acquire Cardax Pharma for consideration of shares of common stock and warrants for the purchase of shares of common stock that will be issued to Cardax Pharmaceuticals, certain investors in Cardax Pharma, and certain other persons. Immediately after the merger, Cardax Pharmaceuticals will own a majority of the issued and outstanding shares of the Koffee Korner common stock.

The closing of the merger is subject to specified terms and conditions, including the divestiture of the existing business operations of Koffee Korner and certain changes to the capital stock of Koffee Korner including the amendment and restatement of its certificate of incorporation and bylaws. On the effective date of the merger, Koffee Korner will change its name to Cardax, Inc., will continue the life science business of Cardax Pharma and we will continue to trade on the OTCBB. We will subsequently change our trading symbol to reflect the name Cardax, Inc.

A copy of the definitive merger agreement is filed as an exhibit to the Current Report on Form 8-K to be filed by Koffee Korner with the United States Securities and Exchange Commission (the “SEC”).

About Cardax Pharma

Cardax Pharma is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (“GRAS”) designation at certain doses. Cardax Pharma is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax Pharma is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-

inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding.

Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions.

Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from its expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

For additional information, please contact:

David G. Watumull
President and CEO
Cardax Pharmaceuticals, Inc.
Cardax Pharma, Inc.
1-808-457-1375
dwatumull@cardaxpharma.com